Advancements in drug development for diarrhea-predominant irritable bowel syndrome

References

• Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150:1393–1407e5.
   Web of Science ®Google Scholar
• Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71–80.
   PubMed Web of Science ®Google Scholar
• Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712–721.e4.
   PubMed Web of Science ®Google Scholar
• Enck P, Aziz Q, Barbara G, et al. Irritable bowel syndrome. Nat Rev Dis Prim. 2016;2:16014.
   PubMed Web of Science ®Google Scholar
• Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150:1393–1407e5.
   Web of Science ®Google Scholar
• Wong RK, Palsson OS, Turner MJ, et al. Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. Am J Gastroenterol. 2010;105:2228–2234.
   PubMed Web of Science ®Google Scholar
• Ford AC, Bercik P, Morgan DG, et al. Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria. Aliment Pharmacol Ther. 2014;39:312–321.
   PubMed Web of Science ®Google Scholar
• Palsson OS, Whitehead WE, Van Tilburg MAL, et al. Development and validation of the Rome IV diagnostic questionnaire for adults. Gastroenterology. 2016;150:1481–1491.
   Web of Science ®Google Scholar
• Dothel G, Barbaro MR, Boudin H, et al. Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology. 2015;148:1002-1011.
   Web of Science ®Google Scholar
• Öhman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7:163–173.
   PubMed Web of Science ®Google Scholar
• Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693–702.
   PubMed Web of Science ®Google Scholar
• Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut. 2009;58:196–201.
   PubMed Web of Science ®Google Scholar
• Carroccio A, Brusca I, Mansueto P, et al. A cytologic assay for diagnosis of food hypersensitivity in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2010;8:254–260.
   PubMed Web of Science ®Google Scholar
• Jeffery IB, Quigley EMM, Öhman L, et al. The microbiota link to irritable bowel syndrome an emerging story. Gut Microbes. 2012;3:572–576.
   PubMedGoogle Scholar
• Tap J, Derrien M, Törnblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152:111–123.e8.
   PubMed Web of Science ®Google Scholar
• Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2006;130:34–43.
   PubMed Web of Science ®Google Scholar
• Zucchelli M, Camilleri M, Nixon Andreasson A, et al. Association of TNFSF15 polymorphism with irritable bowel syndrome. Gut. 2011;60:1671–1677.
   PubMed Web of Science ®Google Scholar
• Camilleri M. Genetics of human gastrointestinal sensation. Neurogastroenterol Motil. 2013;25:458–466.
   PubMed Web of Science ®Google Scholar
• Tack J, Corsetti M, Camilleri M, et al. Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts. Gut. 2017. doi: 10.1136/gutjnl-2016–312230.
   Google Scholar
• Camilleri M. Bile acid diarrhea: prevalence, pathogenesis, and therapy. 2015;9:332–339.
   Google Scholar
• Chumpitazi BP, Cope JL, Hollister EB, et al. Randomised clinical trial: gut microbiome biomarkers are associated with clinical response to a low FODMAP diet in children with the irritable bowel syndrome. Aliment Pharmacol Ther. 2015;42:418–427.
   PubMed Web of Science ®Google Scholar
• Bafutto M, de Almeida JR, Leite NV, et al. Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine. Arq Gastroenterol. 2011;48:36–40.
   PubMedGoogle Scholar
• Camilleri M, Boeckxstaens G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017;66:966–974.
   PubMed Web of Science ®Google Scholar
• Mayer EA, Bradesi S, Chang L, et al. Functional GI disorders: from animal models to drug development. Gut. 2008;57:384–404.
   PubMed Web of Science ®Google Scholar
• European Medical Agen. Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome - CPMP/EWP/785/97 Rev. 1 [Internet]. [cited 2017 Jul 18].
   Google Scholar
• Food and Drug administration. Guidance for Industry Irritable Bowel Syndrome — Clinical Evaluation of Drugs for Treatment. [cited 2017 Jul 18].
   Google Scholar
• Fukudo S, Kinoshita Y, Okumura T, et al. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea : a phase III long-term study. J Gastroenterol. 2016;51:874–882.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. HIGHLIGHTS OF PRESCRIBING INFORMATION - XIFAXAN® (rifaximin) tablets, for oral use. [cited 20 Dec 2017]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021361s012lbledt.pdf
   Google Scholar
• Hartmann G, Honikel KO, Knüsel F, et al. The specific inhibition of the DNA-directed RNA synthesis by rifamycin. Biochim Biophys Acta. 1967;145:843–844.
   PubMed Web of Science ®Google Scholar
• Calanni F, Renzulli C, Barbanti M, et al. Rifaximin: beyond the traditional antibiotic activity. J Antibiot (Tokyo). 2014;667–670.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Heuman DM, Sanyal AJ, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013;8.
   Web of Science ®Google Scholar
• Ma X, Shah YM, Guo GL, et al. Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther. 2007;322:391–398.
   PubMed Web of Science ®Google Scholar
• Dring MM, Goulding CA, Trimble VI, et al. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology. 2006;130:341–348.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA approves two therapies to treat IBS-D.[cited 2017 Nov 28]. Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm448328.htm
   Google Scholar
• Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32.
   PubMed Web of Science ®Google Scholar
• Lembo A, Pimentel M, Rao SS, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151:1113–1121.
   PubMed Web of Science ®Google Scholar
• Pimentel M. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2016;43(Suppl 1):37–49.
   PubMedGoogle Scholar
• Gershon MD. Review article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther. 2004;20:3–14.
   PubMed Web of Science ®Google Scholar
• Garcia-Olmo D, Guadalajara H, Rubio-Perez I, et al. Recurrent anal fistulae: limited surgery supported by stem cells. World J Gastroenterol. 2015;21:3330–3336.
   PubMed Web of Science ®Google Scholar
• Galligan JJ, Pan H, Messori E. Signalling mechanism coupled to 5-hydroxytryptamine4 receptor-mediated facilitation of fast synaptic transmission in the guinea-pig ileum myenteric plexus. Neurogastroenterol Motil. 2003;15:523–529.
   PubMed Web of Science ®Google Scholar
• Suzuki R, Rygh LJ, Dickenson AH. Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci. 2004;25:613–617.
   PubMed Web of Science ®Google Scholar
• Stasi C, Bellini M, Bassotti G, et al. Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome. Tech Coloproctol. 2014;18:613–621.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Yu T, Tang Y, et al. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and metaanalysis of randomized controlled trials. PLoS One. 2017. doi 10.1371/journal.pone.0172846.
   Web of Science ®Google Scholar
• Ford AC, Moayyedi P, Lacy BE, et al. American college of gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109:S2–S26.
   PubMed Web of Science ®Google Scholar
• Lucak S, Chang L, Halpert A, et al. Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therap Adv Gastroenterol. 2017;10:253–275.
   PubMed Web of Science ®Google Scholar
• Miller JL. FDA draws patients into alosetron risk management. Am J Heal Pharm. 2000;57:1736.
   PubMed Web of Science ®Google Scholar
• Garvey TQI, Hyman PE, Hyman PE, et al. Return of alosetron. Expert Opin Drug Saf. 2017;1:1-4.
   Google Scholar
• Chang L, Tong K, Ameen V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan : clinical characteristics, outcomes, and incidences. Am J Gastroenterol. 2010;105:866–875.
   PubMed Web of Science ®Google Scholar
• Cremonini F, Nicandro JP, Atkinson V, et al. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. Aliment Pharmacol Ther. 2012;36:437–448.
   PubMed Web of Science ®Google Scholar
• Fukudo S, Kinoshita Y, Okumura T, et al. Ramosetron reduces symptoms of irritable bowel syndrome with diarrhea and improves quality of life in women. Gastroenterology. 2016;150:258–366e8.
   Web of Science ®Google Scholar
• Matsueda SFK, Ida KHM, Akiho HHH, et al. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea : a randomized, controlled phase II study. Neurogastroenterol Motil. 2017;29:1–10.
   Web of Science ®Google Scholar
• Shiotani A, Kusunoki H, Ishii M, et al. Pilot study of biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1. Neurogastroenterol Motil. 2015;27:82–91.
   PubMed Web of Science ®Google Scholar
• Grover M, Camilleri M. Ramosetron in irritable bowel syndrome with diarrhea: new hope or the same old story? Clin Gastroenterol Hepatol. 2014;12:960–962.
   PubMed Web of Science ®Google Scholar
• Katsumata R, Shiotani A, Murao T, et al. Gender differences in serotonin signaling in patients with diarrhea-predominant irritable bowel syndrome. Intern Med. 2017;56:993–999.
   PubMed Web of Science ®Google Scholar
• Garsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63:1617–1625.
   PubMed Web of Science ®Google Scholar
• Miles TF, Lester HA, Dougherty DA. Allosteric activation of the 5-HT3AB receptor by mCPBG. Neuropharmacology. 2015;91:103–108.
   PubMed Web of Science ®Google Scholar
• Brown PM, Drossman DA, Wood AJJ, et al. The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology. 2011;141:507–516.
   PubMed Web of Science ®Google Scholar
• Clinicaltrial.gov. Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome. [cited 2017 Jul 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT00813098?term=NCT00813098&rank=1
   Google Scholar
• Moore NA, Sargent BJ, Manning DD, et al. Partial agonism of 5-HT3 receptors: A novel approach to the symptomatic treatment of IBS-D. ACS Chem Neurosci. 2013;4:43–47.
   PubMed Web of Science ®Google Scholar
• Manning DD, Guo C, Zhang Z, et al. The discovery of diazepinone-based 5-HT3 receptor partial agonists. Bioorg Med Chem Lett. 2014;24:2578–2581.
   PubMed Web of Science ®Google Scholar
• Jarvis GE, Barbosa R, Thompson AJ. Noncompetitive inhibition of 5-HT3 receptors by citral, linalool, and eucalyptol revealed by nonlinear mixed-effects modeling. J Pharmacol Exp Ther. 2016;356:549–562.
   PubMed Web of Science ®Google Scholar
• Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014;48:505–512.
   PubMed Web of Science ®Google Scholar
• Kariv R, Tiomny E, Grenshpon R, et al. Low-dose naltreoxone for the treatment of irritable bowel syndrome : a pilot study. Dig Dis Sci. 2006;2128–2133.
   PubMedGoogle Scholar
• Kest B, Lee CE, McLemore GL, et al. An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice. Brain Res Bull. 1996;39:185–188.
   PubMed Web of Science ®Google Scholar
• Zhu Y, King MA, Schuller AGP, et al. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in δ opioid receptor knockout mice. Neuron. 1999;24:243–252.
   PubMed Web of Science ®Google Scholar
• Zielińska M, Chen C, Mokrowiecka A, et al. Orally administered novel cyclic pentapeptide P-317 alleviates symptoms of diarrhoea-predominant irritable bowel syndrome. J Pharm Pharmacol. 2015;67:244–254.
   PubMed Web of Science ®Google Scholar
• Sobczak M, Cami-Kobeci G, Sałaga M, et al. Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms. Eur J Pharmacol. 2014;736:63–69.
   PubMed Web of Science ®Google Scholar
• Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011;115:1363-1381.
   PubMed Web of Science ®Google Scholar
• Fujita W, Gomes I, Devi LA. Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities. Br J Pharmacol. 2015;172:375–387.
   PubMed Web of Science ®Google Scholar
• Hojo M, Sudo Y, Ando Y, et al. Mu-opioid receptor forms a functional heterodimer with cannabinoid CB receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci. 2008;108:308–319.
   PubMed Web of Science ®Google Scholar
• Rios C, Gomes I, Devi LA. mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol. 2006;148:387–395.
   PubMed Web of Science ®Google Scholar
• Pfeiffer M, Koch T, Schröder H, et al. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem. 2002;277:19762–19772.
   PubMed Web of Science ®Google Scholar
• Schröder H, Wu DF, Seifert A, et al. Allosteric modulation of metabotropic glutamate receptor 5 affects phosphorylation, internalization, and desensitization of the micro-opioid receptor. Neuropharmacology. 2009;56:768–778.
   PubMed Web of Science ®Google Scholar
• Le Naour M, Lunzer MM, Powers MD, et al. Putative kappa opioid heteromers as targets for developing analgesics free of adverse effects. J Med Chem. 2014;57:6383–6392.
   PubMed Web of Science ®Google Scholar
• Shippenberg TS. The dynorphin/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders? Neuropsychopharmacology. 2009;34:247.
   PubMed Web of Science ®Google Scholar
• Fujita W, Gomes I, Dove LS, et al. Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochem Pharmacol. 2014;92:448–456.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Resource impact report: Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471). [cited 2017 Sept 9]. Available from: https://www.nice.org.uk/guidance/ta471/resources/resource-impact-report-pdf-4595718349
   Google Scholar
• Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016;374:242–253.
   PubMed Web of Science ®Google Scholar
• R V F, Henningfield JE, Cash BD, et al. Eluxadoline demonstrates a lack of abuse potential in phase 2 and 3 studies of patients with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2017;15:1021–1029.e6.
   PubMed Web of Science ®Google Scholar
• Marbury TC, Berg JK, Dove LS, et al. Effect of hepatic impairment on eluxadoline pharmacokinetics. J Clin Pharmacol. 2017;57:1454-1459.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA Drug Safety Communication: FDA warns about increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder Available from: https://www.fda.gov/Drugs/DrugSafety/ucm546154.htm [cited 2017 Sep 28]
   Google Scholar
• Gawron AJ, Bielefeldt K. Risk of pancreatitis following treatment of irritable bowel syndrome with eluxadoline. Clin Gastroenterol Hepatol.2018;16:378-384
   Web of Science ®Google Scholar
• European Medical Association. List of medicinal products under additional monitoring. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicines_under_additional_monitoring/2013/04/WC500142453.pdf [cited 2017 Aug].
   Google Scholar
• Piomelli D, Sasso O. Peripheral gating of pain signals by endogenous lipid mediators. Nat Neurosci. 2014;17:164–174.
   PubMed Web of Science ®Google Scholar
• Barann M, Molderings G, Brüss M, et al. Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol. 2002;137:589–596.
   PubMed Web of Science ®Google Scholar
• Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol. 2008;153: 319–334.
   Web of Science ®Google Scholar
• Howlett AC. Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol. 1995;35:607–634.
   PubMed Web of Science ®Google Scholar
• Yao B, Mackie K. Endocannabinoid receptor pharmacology. Curr Top Behav Neurosci. 2009;1:37–63.
   PubMedGoogle Scholar
• Abalo R, Chen C, Vera G, et al. In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat. Neurogastroenterol Motil. 2015;27:1721–1735.
   PubMed Web of Science ®Google Scholar
• Keenan CM, Storr MA, Thakur GA, et al. AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner. Br J Pharmacol. 2015;172:2406–2418.
   PubMed Web of Science ®Google Scholar
• Picone RP, Khanolkar AD, Xu W. (-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand interacts covalently with a cysteine in helix six and activates the cb1 cannabinoid receptor. Mol Pharmacol. 2005;68:1623-1635.
   PubMed Web of Science ®Google Scholar
• Reichenbach ZW, Schey R. Cannabinoids and GI disorders: endogenous and exogenous. Curr Treat Options Gastroenterol. 2016;14:461–477.
   PubMedGoogle Scholar
• Sanson M, Bueno L, Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil. 2006;18:949–956.
   PubMed Web of Science ®Google Scholar
• Kikuchi A, Ohashi K, Sugie Y, et al. Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. J Pharmacol Sci. 2008;106:219–224.
   PubMed Web of Science ®Google Scholar
• Wong BS, Camilleri M, Busciglio I, et al. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology. 2011;141:1638–1647.
   PubMed Web of Science ®Google Scholar
• Fichna J, Sałaga M, Stuart J, et al. Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides. Neurogastroenterol Motil. 2014;26:470–481.
   PubMed Web of Science ®Google Scholar
• Fichna J, Wood JAT, Papanastasiou M, et al. Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study. PLoS One. 2013; doi: 10.1371/journal.pone.0085073
   PubMed Web of Science ®Google Scholar
• Aloe L, Leon A, Levi-Montalcini R. A proposed autacoid mechanism controlling mastocyte behaviour. Agents Actions. 1993;39:145–147.
   PubMedGoogle Scholar
• Mazzari S, Canella R, Petrelli L, et al. N-(2-Hydroxyethyl) hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol. 1996;300:227–236.
   PubMed Web of Science ®Google Scholar
• Bortolini M, Wright MB, Bopst M, et al. Examining the safety of PPAR agonists - current trends and future prospects. Expert Opin Drug Saf. 2013;12:65–79.
   PubMed Web of Science ®Google Scholar
• Di Cesare Mannelli L, D’Agostino G, Pacini A, et al. Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators Inflamm. 2013;2013.
   Google Scholar
• Guida F, Luongo L, Boccella S, et al. Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Sci Rep. 2017;7:375.
   PubMed Web of Science ®Google Scholar
• Li JJ, Cao JJ, Yang C, et al. Polydatin attenuated food allergy via store-operated calcium channels in mast cell. World J Gastroenterol. 2013;19:3980–3989.
   PubMed Web of Science ®Google Scholar
• Cremon C, Stanghellini V, Barbaro MR, et al. Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. Aliment Pharmacol Ther. 2017;45:1–14.
   Web of Science ®Google Scholar
• Eb R. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of. Eur PMC. 2004;25:31–34.
   Google Scholar
• Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13:35–37.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Carlson P, McKinzie S, et al. Genetic variation in endocannabinoid metabolism, gastrointestinal motility, and sensation. Am J Physiol Gastrointest Liver Physiol. 2008;294:G13–9.
   PubMed Web of Science ®Google Scholar
• Wong BS, Camilleri M, Carlson P, et al. Increased bile acid biosynthesis is associated with irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2012;10:1009–1015.
   PubMed Web of Science ®Google Scholar
• Slattery SA, Niaz O, Aziz Q, et al. Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2015;42:3–11.
   PubMed Web of Science ®Google Scholar
• Vijayvargiya P, Camilleri M, Shin A, et al. Diagnostic methods for bile acid malabsorption in clinical practice. Clin Gastroenterol Hepatol. 2013;11:1232–1239.
   PubMed Web of Science ®Google Scholar
• Wedlake L, Thomas K, Lalji A, et al. Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer : a retrospective chart review and patient questionnaire. Clin Ther. 2009;31:2549–2558.
   PubMed Web of Science ®Google Scholar
• Peleman C, Camilleri M, Busciglio I, et al. Colonic transit and bile acid synthesis or excretion in patients with irritable bowel syndrome – diarrhea without bile acid malabsorption. Clin Gastroenterol Hepatol. 2017;15:720–727.e1.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Acosta A, Busciglio I, et al. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2015;41:438–448.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Vazquez-Roque MI, Carlson P, et al. Association of bile acid receptor TGR5 variation and transit in health and lower functional gastrointestinal disorders. Neurogastroenterol Motil. 2011;23:995.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Carlson P, Acosta A, et al. RNA sequencing shows transcriptomic changes in rectosigmoid mucosa in patients with irritable bowel syndrome-diarrhea: a pilot case-control study. AJP Gastrointest Liver Physiol. 2014;306:G1089–G1098.
   PubMed Web of Science ®Google Scholar
• Mroz MS, Keating N, Ward JB, et al. Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo. Gut. 2014;63:808–817.
   PubMed Web of Science ®Google Scholar
• Walters JRF, Johnston IM, Nolan JD, et al. The response of patients with bile acid diarrhoea to the farnesoid x receptor agonist obeticholic acid. Aliment Pharmacol Ther. 2015;41:54–64.
   PubMed Web of Science ®Google Scholar
• Gavva NR, Treanor JJS, Garami A, et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain. 2008;136:202–210.
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Szallasi A. Transient receptor potential (TRP) channels: a clinical perspective. Br J Pharmacol. 2014;171:2474–2507.
   PubMed Web of Science ®Google Scholar
• Szallasi A, Cortright DN, Blum CA, et al. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov. 2007;6:357–372.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Yang L, Larson S, et al. Decreased miR-199 augments visceral pain in patients with IBS through translational upregulation of TRPV1. Gut. 2016;65:797–805.
   PubMed Web of Science ®Google Scholar
• Lehto SG, Tamir R, Deng H, et al. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J Pharmacol Exp Ther. 2008;326:218–229.
   PubMed Web of Science ®Google Scholar
• Arendt-Nielsen L, Harris S, Whiteside GT, et al. A randomized, double-blind, positive-controlled, 3-way cross-over human experimental pain study of a TRPV1 antagonist (V116517) in healthy volunteers and comparison with preclinical profile. Pain. 2016;157:2057–2067.
   PubMed Web of Science ®Google Scholar
• Karrer T, Bartoshuk L. Effects of capsaicin desensitization on taste in humans. Physiol Behav. 1995;57:421–429.
   PubMed Web of Science ®Google Scholar
• Aniwan S, Gonlachanvit S. Effects of chili treatment on gastrointestinal and rectal sensation in diarrhea-predominant irritable bowel syndrome: a randomized, double-blinded, crossover study. J Neurogastroenterol Motil. 2014;20:400–406.
   PubMed Web of Science ®Google Scholar
• Harrington AM, Hughes PA, Martin CM, et al. A novel role for TRPM8 in visceral afferent function. Pain. 2011;152:1459–1468.
   PubMed Web of Science ®Google Scholar
• Cenac N, Bautzova T, Le Faouder P, et al. Quantification and potential functions of endogenous agonists of transient receptor potential channels in patients with irritable bowel syndrome. Gastroenterology. 2015;149:433–444.e7.
   PubMed Web of Science ®Google Scholar
• Salari P, Abdollahi M. Systematic review of modulators of benzodiazepine receptors in irritable bowel syndrome: is there hope? 2011;17:4251–4257.
   Google Scholar
• Leventer SM, Raudibaugh K, Frissora CL, et al. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther. 2008;27:197–206.
   PubMed Web of Science ®Google Scholar
• Manocha M, Khan WI. Serotonin and GI disorders: an update on clinical and experimental studies. Clin Transl Gastroenterol. 2012;3:e13.
   PubMedGoogle Scholar
• Reiter RJ, Tan DX, Mayo JC, et al. Neurally-mediated and neurally-independent beneficial actions of melatonin in the gastrointestinal tract. J Physiol Pharmacol. 2003;54 Suppl 4:113–125.
   PubMedGoogle Scholar
• Matheus N, Mendoza C, Iceta R, et al. Melatonin inhibits serotonin transporter activity in intestinal epithelial cells. J Pineal Res. 2010;48:332–339.
   PubMed Web of Science ®Google Scholar
• Buendia I, Gómez-Rangel V, González-Lafuente L, et al. Neuroprotective mechanism of the novel melatonin derivative Neu-P11 in brain ischemia related models. Neuropharmacology. 2015;99:187–195.
   PubMed Web of Science ®Google Scholar
• Carocci A, Catalano A, Sinicropi MS. Melatonergic drugs in development. Clin Pharmacol Adv Appl. 2014;6:127–137.
   PubMedGoogle Scholar
• Mosińska P, Socała K, Nieoczym D, et al. Anticonvulsant activity of melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, in mice. Behav Brain Res. 2016;307:199–207.
   PubMed Web of Science ®Google Scholar
• He P, Ouyang X, Zhou S, et al. A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer’ disease. Horm Behav. 2013;64:1–7.
   PubMed Web of Science ®Google Scholar
• Tian S, Laudon M, Han L, et al. Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models. Acta Pharmacol Sin. 2010;31:775–783.
   PubMed Web of Science ®Google Scholar
• Huang L, Zhang C, Hou Y, et al. Blood pressure reducing effects of piromelatine and melatonin in spontaneously hypertensive rats. Eur Rev Med Pharmacol Sci. 2013;17:2449–2456.
   PubMed Web of Science ®Google Scholar
• Storr L-M-U of M. The Effect of Neu-P11 on Symptoms in Patients With D-IBS (Neu-P11) Available from: [cited 2017 Sep 1]. https://clinicaltrials.gov/ct2/show/NCT01558284?term=NCT01558284&rank=1
   Google Scholar
• Papadopoulos V, Baraldi M, Guilarte TR, et al. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006;27:402–409.
   PubMed Web of Science ®Google Scholar
• Rupprecht R, Papadopoulos V, Rammes G, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov. 2010;9:971–988.
   PubMed Web of Science ®Google Scholar
• Whitehead WE, Duffy K, Sharpe J, et al. Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2016;45:14-26.
   PubMed Web of Science ®Google Scholar
• EvaluatePharma. EvaluatePharma – USA sales by indication (IBS-D). [cited 2017 Sep 9].
   Google Scholar
• Beckers AB, Weerts ZZRM, Helyes Z, et al. Review article: transient receptor potential channels as possible therapeutic targets in irritable bowel syndrome. Aliment Pharmacol Ther. 2017;46:938-952.
   PubMed Web of Science ®Google Scholar
• Balestra B, Vicini R, Cremon C, et al. Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons. Neurogastroenterol Motil. 2012;24:1118-e570.
   Web of Science ®Google Scholar
• Barbaro MR, Di Sabatino A, Cremon C, et al. Interferon-γ is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism. Am J Physiol Gastrointest Liver Physiol. 2016;310:G439–G447.
   PubMed Web of Science ®Google Scholar